Bought a first position of this one. I think it has great potential the next 6-9 months. Great beneficial technology imo. First mover advantage – no competitors. In view of Covid-19 the technology has in particular the advantage of reducing length of stay at hospital. Presentation May 2020 https://ir.motusgi.com/ Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. Market Cap: ~ $34 million Cash: $21.5 million (likely ~ $14.5 million at the end of Q2) 50% cost reduction measures implemented. Moving forward quarterly burn rate is ~ $3 million.
Very interesting interview with the CEO of Motus. In my opinion it shows the great potential of the company moving forward. Some notable excerpts – 15:30 min “Before Covid the number one value proposition we bring to the market is the ability to impact patient flow, avoiding delays or repeat procedures… In the era of Covid many of our Docs said the value proposition is now even more amplified.” Interview with CEO 15 June 2020 https://www.vifiresidechat.com/motusgi
I sold this one two months ago with a 5% loss when the stock moved up on the private placement announcement. My entry point was way to high back then. Now at the current share price in the low 0.70 this is a great buy imo. Market Cap is below cash right now. Bought a first position today again. The single healthcare focused institutional investor purchased shares in the private placement at a price of $1.145 two months ago. Motus GI Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market August 28, 2020 https://www.motusgi.com/news-media/...unces-pricing-of-10-million-registered-direct
Looks like the low 0.70 were a good entry point. I am confident the share price will move higher than $1 soon...
Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies December 02, 2020 FORT LAUDERDALE, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a collaboration with Dr. Nirav Thosani, Director of Advanced Endoscopy, Memorial Hermann Hospital in Houston, Texas, to incorporate the Company’s Pure-Vu® System with the aim of improving efficiencies and clinical outcomes of inpatient colonoscopy procedures at Memorial Hermann Hospital, for patients who present with inadequate bowel preparation. The Memorial Hermann Hospital is a flagship hospital within the Memorial Hermann System, which is one of the largest not-for-profit health systems in Texas, owning and operating 14 hospitals. https://ir.motusgi.com/press-releas...-memorial-hermann-hospital-partner-to-improve
Now above a buck @ $1.11 Current market cap of $36 million is still relatively low imo with 23.7 million cash as of 30 September 2020.
Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System’s Universal Method to Mount on the End of Most Commercial Colonoscopes January 11, 2021 Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels https://ir.motusgi.com/press-releas...ands-intellectual-property-portfolio-with-u-s
Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration January 15, 2021 Regulatory approval for enhanced system is a key milestone that supports evaluation of strategic partnership opportunities in the EU - - - U.S. commercial rollout of Pure-Vu® GEN2 System enhancements initiated in Q4 2020 https://ir.motusgi.com/press-releas...ounces-european-clearance-of-enhanced-pure-vu
